Clinical trial · no report yet · Phase 2
PACIFIC 6
A Study to Determine Safety of Durvalumab After Sequential Chemo Radiation in Patients With Unresectable Stage III Non-Small Cell Lung Cancer
- NCT03693300 ↗
- Completed
- AstraZeneca
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 20 | |
| Podcasts | 10 | |
| YouTube | 6 |
The trial
ClinicalTrials.gov- Official title
- A Phase II, Open-Label, Multi-Centre, International Safety Study of Durvalumab Following Sequential Chemotherapy and Radiation Therapy in Patients With Stage III, Unresectable Non-Small Cell Lung Cancer (PACIFIC 6)
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Non-small Cell Lung Cancer (NSCLC)
- Interventions
- Durvalumab
- Arms
- WHO/ECOG PS 0 to 1 Cohort · Experimental
- WHO/ECOG PS 2 Cohort · Experimental
- Enrollment
- 117
- Primary outcomes
- Number of Patients With Grade 3 and Grade 4 Treatment-related Adverse Events (TRAEs)
- Sponsor
- AstraZeneca
- Start
- Apr 16, 2019
- Primary completion
- Dec 13, 2022
- Results posted
- Yes
- Registry record
- NCT03693300 · updated Jun 18, 2024
Publications
linked from the registry- Garassino MC, Mazieres J, Reck M, Chouaid C, Bischoff H, Reinmuth N, Cove-Smith L, Mansy T, Cortinovis D, Migliorino MR, Delmonte A, Sanchez JG, Chara Velarde LE, Bernabe R, Paz-Ares L, Perez ID, Trunova N, Foroutanpour K, Faivre-Finn C. Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial. J Thorac Oncol. 2022 Dec;17(12):1415-1427. doi: 10.1016/j.jtho.2022.07.1148. Epub 2022 Aug 9. PubMed 35961520